Dual bronchodilator versus inhaled corticosteroid/long-acting β < sub > 2 < /sub > -agonist in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials

CONCLUSIONS: Dual bronchodilator is superior to ICS/LABA in improving lung function and is associated with a lower risk of pneumonia in patients with COPD. There are no significant differences in other efficacy and safety profiles between these two maintenance treatments.PMID:33601247 | DOI:10.1016/j.intimp.2021.107447
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Source Type: research